.png){kind=icon}
.png){kind=icon}
Return
Progress in Thymic Malignancy Care: The Imperative for Global Standards and Collaboration
.png){kind=icon}
PRE
AI
G
S
F
A
M
F
P
H
V
E
DOI：10.1093/ejcts/ezag178.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Thymic Epithelial Tumors (TETs), including thymoma, thymic carcinoma, and Thymic Neuroendocrine Neoplasms (T-NEN), are rare, representing approximately 1% of malignancies. The first classification (1961, invasive and non-invasive) was followed by >15 other stage classification systems, most notably perhaps the 1981 Masaoka classification (Figure 1).1–3 The Masaoka system was based on 93 patients and the 1994 Koga modification on 79 patients, and applied only to thymoma. The lack of a universally adopted stage classification hampered the ability to compare clinical studies—a crucial deficit in a rare disease. Furthermore, aspects of the classification systems were vaguely defined, and even centres using the same system often interpreted stage designations differently.
Journal
E
IF:
3
Papers:
1.5W
Citations:
1.7W
Organization
Cited Papers